PTC Therapeutics (PTCT) Gets a Hold Rating from Cowen & Co.


Cowen & Co. analyst Joseph Thome maintained a Hold rating on PTC Therapeutics (PTCT) on July 26 and set a price target of $50.00. The company’s shares closed last Friday at $47.83.

According to TipRanks.com, Thome is ranked #5745 out of 6880 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PTC Therapeutics with a $58.75 average price target, which is a 24.6% upside from current levels. In a report issued on July 20, Credit Suisse also downgraded the stock to Hold with a $53.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $59.89 and a one-year low of $30.79. Currently, PTC Therapeutics has an average volume of 782.3K.

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts